First treatment

to prevent and treat HPV dependent cervical lesions

What is HPV?

HPV is the most common sexually transmitted virus among the population that, in most cases, the body eliminates spontaneously in an average of two years. However, sometimes the virus can become persistent, which is the main risk factor for developing lesions that, over time and as long as they are not detected and treated properly, could progress to a more serious stage.

What is PAPILOCARE®?

PAPILOCARE® Vaginal Gel is the first treatment that has been scientifically proven to be highly effective in eliminating not only the human papillomavirus (HPV), but also the initial precancerous lesions of the cervix. to prevent and treat the HPV-dependent cervical lesions, for HPV+ Patients without lesions, HPV+ Patients with ASCUS or LSIL.

When should I use it?

PAPILOCARE® Vaginal Gel clinical uses: Controlling and re-epithelizing the cervical transformation zone to prevent the risk of HPV-induced lesions (LSIL).

Coadjacent treatment of HPV-induced intra-epithelial lesions.
Repairing and re-epithelizing lesions of the cervical-vaginal mucosa.
Rebalancing vaginal microbiota.
Improving vaginal health.

Creating the conditions for rapid healing of lesions caused by scratching due to burning and pruritus

How does it work?

Papilocare® Vaginal Gel is specifically designed to activate the two modifiable factors that can influence HPV persistence or clearance and acts by forming a film on the cervical mucosa that creates a defensive barrier to prevent the risk of HPV integration and quickly reduces the discomfort caused by the infection by accelerating the natural healing process.

These functions are possible thanks to its innovative technology and its unique formulation based on seven natural components, including Coriolus versicolor extract, a fungus widely used in traditional Chinese medicine, and Bioecolia®, a prebiotic that promotes the growth of beneficial bacteria such as Lactobacillus crispatus.

In addition, in its formulation it also has hyaluronic acid, beta-glucan, centella asiatica, neem extract and aloe vera extract. Thanks to this powerful combination, the vaginal gel provides a multiple action:

Re-epithelializing.
Prebiotic: stimulates the growth of the beneficial bacterial microbiota and rebalances the microbiota in the cervico- vaginal area.
Moisturizing: helps maintain the correct elasticity of internal tissues.
Antioxidant: maintains the natural structure and functionality of the skin and mucous membranes, as well as improving the barrier function of the epithelium.
Repairing: of the injured mucous membranes.
Emollient: favors the natural healing process.

How to use PAPILOCARE®?

First month:
daily application for 21 consecutive days or until the first day of menstruation and rest during bleeding.

Subsequent months:
One application on alternate days for 21 days or until the first day of menstruation and rest during bleeding.

To consider:

The recommended dose for each application is a single-dose cannula or 3ml with a reusable applicator.
Interruption of treatment during menstruation
Papilocare® Vaginal Gel should be used preferably before going to bed and is compatible with the use of condoms.

Scientific Evidence

The efficacy of Papilocare® Vaginal Gel has been studied and demonstrated in several international clinical trials in which more than 600 patients have participated. Among all of them, the PALOMA clinical trial stands out, the results of which have been recently published in the American scientific journal.

“Journal of Lower Genital Tract Diseases”

“Paloma Study” concludes that treatment with Papilocare has demonstrated a better clinical benefit than the conventional watchful waiting approach in clinical practice for total and high-risk HPV patients in terms of its efficacy to treat HPV-related cervical lesions and to clear all HPV strains after a single 6-month period. It has demonstrated an adequate safety and tolerability and confers additional benefits such as higher re-epithelization, stress reduction, and high treatment adherence.

In addition, the PAPILOBS observational study has also been developed, and five other independent studies carried out by public hospitals in Spain and Italy.

The results obtained are similar in all of them and, among the treatment logos, the following stand out:

Normalization of low-grade lesions of the cervix in 88% of patients infected with high-risk HPV after six months of treatment, compared to 56% of patients who were treated.
High-risk HPV test negative after treatment in 63% of patients who followed the Papilocare® Vaginal Gel regimen, compared to 40% of the control group.